

# Delirium is a presenting symptom of COVID-19 in frail, older adults: a cohort study of 322 hospitalised and 535 community-based older adults

Maria Beatrice Zazzara MD\*<sup>1,7</sup>, Rose S. Penfold BMBCCh\*<sup>1</sup>, Amy L. Roberts PhD\*<sup>1</sup>, Karla A. Lee MSc<sup>1</sup>, Hannah Dooley PhD<sup>1</sup>, Carole H. Sudre PhD<sup>2</sup>, Carly Welch MRes<sup>3</sup>, Ruth C. E. Bowyer PhD<sup>1</sup>, Alessia Visconti PhD<sup>1</sup>, Massimo Mangino PhD<sup>1,5</sup>, Maxim B. Freydin PhD<sup>1</sup>, Julia S. El-Sayed Moustafa PhD<sup>1</sup>, Kerrin Small PhD<sup>1</sup>, Benjamin Murray MSc<sup>2</sup>, Marc Modat PhD<sup>2</sup>, Jonathan Wolf MA<sup>4</sup>, Sebastien Ourselin PhD<sup>2</sup>, Finbarr C. Martin MD<sup>6</sup>, Claire J. Steves\* PhD<sup>1</sup>, Mary Ni Lochlainn\* MBBCCh BAO<sup>1</sup>

<sup>1</sup>Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH

<sup>2</sup>School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, SE17EH, London, UK

<sup>3</sup>Institute of Inflammation and Ageing, University of Birmingham, B15 2TT

<sup>4</sup>Zoe Global Limited, 164 Westminster Bridge Road, London SE1 7RW, UK

<sup>5</sup>NIHR Biomedical Research Centre at Guy's and St Thomas' Foundation Trust, London SE1 9RT, UK.

<sup>6</sup>Population Health Sciences, King's College London, Westminster Bridge Road, SE17EH, London, UK

<sup>7</sup>Department of Gerontology, Neuroscience and Orthopedics, Sacred Heart Catholic University, Rome, Italy

\*These authors contributed equally to the work

Corresponding Author: Mary Ni Lochlainn  
The Department of Twin Research and Genetic Epidemiology,  
King's College London,  
St Thomas' Campus,  
Lambeth Palace Road,  
London,  
SE1 7EH.  
Tel: +442071885555  
Email: [mary.ni\\_lochlainn@kcl.ac.uk](mailto:mary.ni_lochlainn@kcl.ac.uk)

Word count: 2499

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**



**Abstract:**

Background: Frailty, increased vulnerability to physiological stressors, is associated with adverse outcomes. COVID-19 exhibits a more severe disease course in older, co-morbid adults. Awareness of atypical presentations is critical to facilitate early identification.

Objective: To assess how frailty affects presenting COVID-19 symptoms in older adults.

Design: Observational cohort study of hospitalised older patients and self-report data for community-based older adults.

Setting: Admissions to St Thomas' Hospital, London with laboratory-confirmed COVID-19. Community-based data for 535 older adults using the COVID Symptom Study mobile application.

Subjects: Hospital cohort: patients aged 65 and over (n=322); unscheduled hospital admission between March 1<sup>st</sup>, 2020-May 5<sup>th</sup>, 2020; COVID-19 confirmed by RT-PCR of nasopharyngeal swab. Community-based cohort: participants aged 65 and over enrolled in the COVID Symptom Study (n=535); reported test-positive for COVID-19 from March 24<sup>th</sup> (application launch)-May 8<sup>th</sup>, 2020.

Methods: Multivariate logistic regression analysis performed on age-matched samples from hospital and community-based cohorts to ascertain association of frailty with symptoms of confirmed COVID-19.

Results: Hospital cohort: significantly higher prevalence of delirium in the frail sample, with no difference in fever or cough. Community-based cohort: significantly higher prevalence of probable delirium in frailer, older adults, and fatigue and shortness of breath.

Conclusions: This is the first study demonstrating higher prevalence of delirium as a COVID-19 symptom in older adults with frailty compared to other older adults. This emphasises need for systematic frailty assessment

and screening for delirium in acutely ill older patients in hospital and community settings. Clinicians should suspect COVID-19 in frail adults with delirium.

### **Background:**

COVID-19, an acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a significant threat to the older population, who are at increased risk from infection, hospitalisation and death[1,2]. In a study from Wuhan, China, over 70% of 339 patients over 60 years of age with COVID-19 were classified as severe or critical, with a case fatality rate of 19% and median survival of 5 days following admission[3]. In Italy, the highest case fatality rate was observed among older, male patients with multiple comorbidities[4] and in an American study, adults >65 years old represented 80% of COVID-19 fatalities[5]. Vulnerability within the older population might partially be explained by a greater number and severity of chronic diseases[6] and immunosenescence[7,8]. It is imperative to rapidly identify and contain infection within this group.

Prevalent symptoms reported in patients with confirmed COVID-19 infection from a variety of international settings are summarised in Table 1. However, it is well-documented that presenting symptoms vary with age for many diseases, including respiratory infections[9,10,11]. Symptoms including delirium, generalised weakness, malaise, anorexia, headache, dizziness, falls and functional decline are more common in older people. Less typical presentations of COVID-19 in older adults have been documented in case reports and small cohort studies (n<60), with symptoms including weakness, headache, delirium and an absence of fever or cough[12,13,14]. In work by our research group using point-of-care testing for COVID-19 in older adults, hypothermia was noted to be an early clinical sign in a minority of patients[15].

Frailty, an increased vulnerability to physiological stressors[16], confers increased risk of adverse health outcomes including mortality, falls, fractures, comorbidities, hospitalisation, and disability[16,17]. Frailty is also associated with increased likelihood of hospital-acquired complications, such as delirium, falls or deconditioning. Recent National Institute for Health and Care Excellence (NICE) guidelines in the UK recommend that all adult patients over 65 years old should be assessed for frailty on hospital admission to guide appropriate management and advanced care planning, using the Clinical Frailty Scale (CFS) where relevant[18]. However, no study has reported on effects of frailty on symptoms of COVID-19, despite calls for data in this important area[19].

We use point-of-care data from patients admitted to a large UK hospital trust, supported by community-based COVID Symptom Study mobile application (“app”) data, to assess how frailty affects presentation of confirmed COVID-19 infection in older adults.

## **Methods:**

### **Participants**

This study uses two cohorts.

(i) Hospital cohort:

Point-of-care clinical data was collected on all patients aged 65 years and above with unscheduled admission to Guy's and St Thomas' Hospital, London, between March 1<sup>st</sup>-May 5<sup>th</sup>, 2020 with suspected or confirmed COVID-19 infection. This was collected as part of the international COVIDCollab study, led by the Geriatric Medicine Research Collaborative[20]. All data is routinely collected and includes age, sex, body mass index (BMI), co-morbidities, CFS[21,22] and presenting symptoms. Full data collection template available at <https://www.gemresearchuk.com/covid-19>.

Only laboratory-confirmed cases of COVID-19 infection (RT-PCR of nasopharyngeal swab) were included in this study. For patients readmitted during the study period, data from index admission was used.

(ii) Community-based cohort:

This comprised community-dwelling older people who had submitted data via the COVID Symptom Study app, developed by Zoe Global Limited, with scientific input from researchers and clinicians at King's College London and Massachusetts General Hospital, Boston. The app was launched in the UK on March 24<sup>th</sup> and became available in the US on March 29<sup>th</sup>, 2020. It captures self-reported information on COVID-19 symptoms and healthcare visits. On first accessing the app, users record location, age and health risk factors. Since the CFS requires assessment by a healthcare professional, it was not feasible here. Users instead completed a PRISMA-7 questionnaire (a 7-item screening tool)[23] adapted for large-scale app usage, to assess level of frailty (Supplementary Table SP1). PRISMA-7 has been validated for use in older adults[24] and has good validity compared to the CFS[25]. The app was upgraded in April 2020 to allow family members or care-givers to submit data by-proxy, with consent. This has increased numbers of reporting older, frailer participants.

Consent to data analysis and sharing was obtained when individuals enrolled in the app. UK data up to May 8<sup>th</sup>, 2020 were inspected and, as part of the quality control (QC) stage, invalid BMI (<15 and >55) and age entries (<18 years) removed. QC was performed by an automated python script developed independent of data analysis. The total dataset comprised 2,848,396 individuals, 11,206 of whom had reported a positive COVID-19 test. This was filtered to include only those aged 65 years and above. All longitudinal entries were condensed per person to form a binary metric recording whether the person had experienced each of the 14 symptoms (below) during the study period.

### **Measurements**

Delirium was defined as a clinically documented delirium diagnosis on admission in the hospitalised cohort and “Yes” to the following question in the community-based cohort: ‘Do you have any of the following symptoms: confusion, disorientation or drowsiness?’

### **Analyses**

Descriptive statistics were used to describe demographic and key clinical characteristics of the study populations: overall and according to frailty. Frailty was classified as a binary variable:  $CFS \geq 5$  = frail;  $CFS < 5$  = not frail for the hospital cohort and  $PRISMA7 \geq 3$  = frail;  $PRISMA7 < 3$  = not frail in the community-based cohort. A binary temperature classification was used in the hospitalised cohort, based on a previous large observational cohort study[26]:  $\geq 37.5^\circ C$  = fever;  $37.5 <$  afebrile.

Continuous variables were expressed as mean +/- standard deviation, and categorical variables as frequencies by absolute value and percentages (%). Differences in proportions and means of covariates between subjects with and without frailty were assessed using Wilcoxon’s test for continuous variables and Fisher’s exact test for categorical variables.

Following age-matching by frailty status in the hospitalised cohort (n=210), multivariable logistic regression analysis was performed to assess whether frailty predicts symptoms of confirmed COVID-19 infection on hospital admission, including fever, cough and delirium. BMI and sex were covariates.

Following age-matching by frailty status in the community-based cohort (n=238), multivariable logistic regression analysis was performed to assess whether frailty predicts symptoms of reported confirmed COVID-19 infection. Symptoms analysed included delirium, fever, persistent cough, fatigue, myalgia, shortness of breath, diarrhea, anorexia, abdominal pain, hoarse voice, anosmia/dysgeusia, headache, chest pain and pharyngodynia. BMI and sex were covariates.

Data analysis and graphics were performed in the R statistical environment (version 4.0) using the Tidyverse packages.

## **Results:**

### **Hospital cohort:**

Baseline characteristics of the unmatched hospital study cohort are summarised in Supplementary Table SP2. Mean age of 322 individuals with confirmed COVID-19 RT-PCR was 78.58 years (standard deviation (SD) +/- 7.93); 154 (48%) were females. 165 (51%) patients were classified as frail.

After age-matching, difference in mean age between the frail (77.92 +/- SD 6.64 years) and non-frail group (77.85 +/- SD 7.04 years) was non-significant (Wilcoxon's  $p > 0.05$ ). The proportion of females was 39% in both groups. BMI differences between the frail and non-frail groups were non-significant (Figure 1 a-c and Table 2). Comorbidities of the matched study cohort according to frailty status are summarised in Table 2. There was a higher proportion of respiratory disease and dementia in the frail compared to non-frail group, but no significant differences in prevalence of cardiovascular disease, diabetes, psychiatric disease or cancer (Table 2).

After age-matching, delirium was reported in 40 (38%) of frail and 13 (12%) of non-frail patients with COVID-19 (Table 3). Frailty was found to significantly predict delirium ( $P$ -value: 0.013; Odds Ratio (OR) (95% Confidence Interval (CI)) = 3.22 (1.44, 7.21)) after false discovery rate (FDR) correction for multiple testing (Figure 2 and Table 3). There were no significant differences between frail and not frail for other symptoms (fever (temperature  $\geq 37.5$ C) and cough).

### Community-based cohort:

The proportion of total COVID Symptom Study app users  $\geq 65$  years of age was 334,544/ 2,848,396 (11.7%). Baseline characteristics of the unmatched study population are summarised in Supplementary Table SP2. 192 (36%) were classified as frail. 77% of the 192 frail participants with a reported positive COVID-19 test were reporting-by-proxy. In the frail group, delirium was present in 94/192 (49%) (self-reported 20/44 (45%); reported-by-proxy 74/148 (50%)). Baseline characteristics of the age-matched cohort are summarised in Figure 1 (d-f) and Table 2. Comorbidities are summarised in Table 2.

After age-matching, frailty was found to significantly predict delirium ( $P$ -value 0.038; OR (95% CI) = 2.29 (1.33, 4.00)), after FDR correction for multiple testing (Table 3). Frailty also predicted fatigue ( $P$ -value: 0.038; OR = 2.23 (1.27, 3.96)) and shortness of breath ( $P$ -value: 0.043; OR = 2.00 (1.19, 3.39)). There were no significant differences between frail and not frail for the other 11 symptoms analysed (Table 3 and Supplementary Table SP3).

### Discussion:

In this study, we demonstrate that prevalence of delirium and confusion is significantly higher in frail compared to non-frail older adults with COVID-19, highlighting both that a frailty assessment is fundamental, but also a systematic evaluation of change in mental status needs to be included when assessing this population. Delirium is associated with greater morbidity and mortality amongst older adults[27] and may be the only presenting symptom of COVID-19 in this highly vulnerable population.

COVID-19 disproportionately affects the older population, partly because of the increased prevalence of frailty. Frail adults in residential settings may be at particular risk of transmission of respiratory illness. Case reports of COVID-19 outbreaks in nursing and residential homes have been published, highlighting the risks of infection in residential settings and a high case fatality[28]. Aside from residential facilities, many frail older adults are dependent on home care packages, with movement of care workers between residences. It is imperative that differences in COVID-19 presentation as a result of frailty are understood to prompt rapid diagnosis, isolation

and contact tracing to limit outbreaks, and to clinical assessment and treatment. Our findings alert clinicians to the need to identify frailty and look for atypical COVID-19 presentations.

We also identified self-reported fatigue and shortness of breath as more common amongst adults with frailty. Higher prevalence of fatigue is consistent with a decrease in physiological reserve conferred by frailty.

Early identification of frailty facilitates a differential, targeted clinical approach, focusing not only on “typical” COVID-19 symptoms (*e.g.* fever and cough) but also on symptoms, such as delirium, demonstrated here to be more common in frail older adults. The importance of comprehensive frailty assessment in acute clinical settings and the community is nationally recognised[29,30]. Rapid NICE guidance produced in response to the COVID-19 outbreak outlines the importance of identifying those at increased risk of poor outcomes and perhaps less likely to benefit from critical care admission[18,30]. Delirium is frequently under-recognised in hospitalised populations[27]. Recognition of delirium necessitates a thorough investigation for underlying causes and management requires a tailored, patient-centred approach.

Delirium is a frequent complication of hospitalisation for older adults[31] and for patients admitted to critical care of all ages[32]. Whilst pathophysiology is not fully understood, neuroinflammation has been hypothesised to play a key role in its development[32]. In the context of COVID-19, few of the early descriptive studies included delirium or new confusion[33], emphasising the importance of our finding. A recent case study described acute confusion in an older patient with no pre-existing cognitive impairment presenting with COVID-19[14]. In a retrospective study of 214 patients from China, Mao *et al.* described neurological manifestations of COVID-19 and reported ‘impaired consciousness’ in 7.5% of patients, some of which may represent delirium. Other central nervous system (CNS) manifestations of COVID-19 infection reported were headache, dizziness, acute cerebrovascular disease, ataxia and seizures. These were significantly more common in severe infections and in older and comorbid patients[34]. In addition, non-neurological triggers may be important in delirium. Hypoxia, common in COVID-19 infections[35], is a well-recognised cause of delirium[36]. In addition, electrolyte disturbance, dehydration, and tachycardia common to all viral infections may play a role. Some have suggested that reduced patient contact during the pandemic, for protection of staff and other patients and because of time taken to don personal protective equipment, may be contributing to missed or delayed diagnoses of fluctuant delirium and acute confusion in these patients[37,38].

A number of other coronaviruses have shown significant neurotropism in animal models [39,40]; it is plausible that SARS-CoV-2 displays this property. Indeed, SARS-CoV-2 was found in cerebrospinal fluid of a reported case of COVID-19 encephalitis in Beijing[41]. Different mechanisms have been proposed to explain neurological involvement in COVID-19. The virus could reach the CNS via a compromised blood-brain barrier, or migrate via neuronal pathways, infecting peripheral sensory or motor nerve endings[42], leading to subsequent neurological damage and neuroinflammation. Some authors have proposed that angiotensin-converting enzyme 2 (ACE2), identified as the functional receptor for SARS-CoV-2, also expressed in the brain[43], could play a crucial role in mediating the inflammatory response in COVID-19 infection[34,44].

### **Limitations**

There are several limitations to this study. For the hospital cohort, admissions data were collected retrospectively from electronic health records. CFS was not always documented systematically and, in approximately one-third of cases, had to be retrospectively calculated using relevant information from admission clerking.

In the community-based cohort, COVID-19 test result and symptoms were self-reported and entered directly by participants or by-proxy. The proportion of total app users  $\geq 65$  years of age is 11.7%, whereas only 4.8% of app users with a confirmed positive COVID-19 test were  $\geq 65$  years of age. Since 18.3% of the UK population are aged over 65[45], older adults overall, and especially laboratory-tested for COVID-19, are likely to be under-represented. Sampling using a mobile application will under-represent individuals without mobile devices and is likely to under-represent those severely affected by the disease. These biases may mean we underestimate the differences in symptoms in frail people in the community study. The fact that the most significant finding from the community-based study was recapitulated in the clinical study is reassuring. Furthermore, of app users  $\geq 65$  years of age, 16.4% are categorised as frail. This is a similar proportion to the 15-20% of older adults categorised as moderate or severely frail during validation of the electronic Frailty Index[46].

For community-based data, note that COVID-19 tests were not widely available in the UK at the time of study[47,48]. Participants were likely tested because they displayed severe symptoms, were in contact with confirmed cases, were healthcare workers or had travelled abroad to a risk area early in the outbreak. Additionally, the app captures data on whether participants have ever been diagnosed with COVID-19; some individuals may have previously tested positive but were no longer symptomatic when they enrolled.

### **Conclusion:**

This is the first study reporting that frail patients with COVID-19 present with a significantly higher prevalence of delirium than non-frail patients, using hospital and community-based cohorts. Our data emphasises the need for systematic assessment of frailty and delirium as critical components when assessing acutely ill patients in both hospital and community settings. Clinicians should suspect COVID-19 in frail patients presenting with delirium. This is especially important in care homes and long-term care facilities, where resident populations are vulnerable to respiratory disease outbreaks. Early detection facilitates implementation of infection control measures and appropriate personal protective equipment to avoid catastrophic spread and reduce mortality amongst frail older adults.

### **Ethics:**

COVIDCollab project service evaluation approved by Guy's and St Thomas' NHS Trust audit leads. Reference number 10777.

The Covid Symptom Study App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRS-19/20-18210. All subscribers provided consent when signing up for the app.

### **Data sharing:**

COVIDCollab data is available upon application to the Geriatric Medicine Research Collaborative

<https://www.gemresearchuk.com/>.

App data used in this study is available to bona fide researchers through UK Health Data Research using the following link <https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f6>

### **Funding:**

Support for this study was provided by the NIHR-funded Biomedical Research Centre based at GSTT NHS Foundation Trust. Investigators also received support from the Wellcome Trust, the MRC, BHF, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL.

### **Acknowledgements:**

The app was developed by Zoe Global Limited with input from King's College London and Massachusetts General Hospital.

The Principal Investigator and corresponding author (MNL) had full access to all the data in this study and takes full responsibility for the integrity of the data and the accuracy of data analysis.

All authors listed were responsible for aspects of study design, data collection and analysis and writing of manuscript and meet criteria for authorship. MBZ, RSP, ALR, CW, HD and MNL were involved in data collection, cleaning and statistical analysis of the hospital dataset. BM produced the data cleaning script for the app dataset. ALR, KAL, CHS, RCEB, AV, MM, MBF, JSESM, KS, MM, JW and SO were involved in data collection, processing and analysis of the app dataset. MBZ, RSP, ALR, KAL, HD, CHS, CW, RCEB, AV,

MM, FCM, CJS and MNL drafted the initial manuscript. All authors contributed to and reviewed the final manuscript to be published.

We would like to acknowledge the following COVIDCollab collaborators, responsible for hospital data collection: Rishi Iyer, Rachael Anders, Lindsay Hennah, Gitanjali Amaratunga, Abigail Hobill, Cassandra Fairhead, Amybel Taylor, Henry Maynard, Marc Osterdahl, Maria Dias, Taha Amir, Natalie Yeo, Jamie Mawhinney, Hamilton Morrin, Li Kok, Luca Scott, Aiden Haslam, Gavriella Levinson, Stephanie Mulhern, Stephanie Worrall, Thurkka Rajeswaran, Katherine Stamboullouian, Sophie McLachlan, Karla Griffith, Daniel Muller, Alice O' Doherty, Baguiasri Mandane, Irem Islek, Alexander Emery, John Millwood-Hargrave, Andra Caracostea, Laura Bremner, Arjun Desai, Aneliya Kuzeva, Carolyn Akladios, Mettha Wimalasundera, Mairead Kelly, Sally Aziz, Sinead O'Dwyer, Rupini Perinpanathan, Anna Barnard, Nicole Hrouda, Ismini Panayotidis, Nirali Desai, Hannah Gerretson, Rebecca Lau, Zaynub Ghufloor, Hanna Nguyen, Torben Heinsohn, Jack Cullen, Eleanor Watkins, Vaishali Vyas, Daniel Curley, Niamh Cunningham, Vittoria Vergani, Kelvin Miu, Jack Stewart, Nicola Kelly, Lara Howells, Benyamin Deldar, Ross Sayers, Gracie Fisk, Sri Sivarajan, Tahmina Razzak, Helen Ye, Samiullah Dost, Nikhita Dattani, Catherine Wilcock, Gabriel Lee, Jodie Acott, Hannah Bridgwater, Antia Fernandez, Hesham Khalid, Katherine Hopkinson, Deirdre Green, Hejab Butt, Ayushi Gupta, Madeleine Garner, Hazel Sanghvi, Madeleine Daly, Emily Ross-Skinner, Shefali Patel, Danielle Lis. (All affiliated to Guy's and St Thomas' Hospital NHS Foundation Trust).

Written permission obtained to include the names of all individuals listed.

The authors acknowledge use of the research computing facility at King's College London, *Rosalind* (<https://rosalind.kcl.ac.uk>).



**Tables and Figures:**

**Table 1. Studies describing the frequency of symptoms in laboratory confirmed SARS-CoV-2**

Study	Participants	Study Methods	Symptoms reported (% of cases)
Guan et al.[26]  China	1099 patients with laboratory confirmed SARS-CoV-2  Median age 47 years 58.1% Male  Severe disease n = 173 Non-severe disease n = 926	552 hospitals  Retrospective observational study  Data compared between severe and non-severe disease (severe = death or requirement for ICU admission/mechanical ventilation)	Fever (43.8% on admission, 88.7% during hospitalization) Cough (67.8%) Fatigue (38.1%) Sputum production (33.7%) Shortness of breath (18.7%) Myalgia or arthralgia (14.9%) Sore throat (13.9%) Headache (13.6%) Chills (11.5%) Nausea or vomiting (5.0%) Diarrhea (3.8%)
Wang et al. [49]  China	138 patients  Median age 56 years 54.3% Male	Single site  Retrospective observational study	Fever (98.6%) Cough (86.2%) Myalgia or fatigue (34.8%) Dyspnea (31.2%) Expectoration (26.8%) Sore throat (17.4%) Diarrhea (10.1%) Headache or dizziness (6.5%) Nausea and vomiting (3.6%) Other symptoms* (42.0%)  * chilliness; conjunctival congestion; anorexia; abdominal pain; constipation; heart palpitations
Du et al.[50]  China	85 patients with laboratory confirmed SARS-CoV-2  Median age 65.8 years 72.9% Male	2 hospitals  Retrospective observational study  All cases fatal	Fever (91.8%) Dyspnea (70.6%) Shortness of breath (58.8%) Fatigue (58.8%) Anorexia (56.5%) Expectoration (37.6%) Dry cough (22.4%) Diarrhea (18.8%) Myalgia (16.5%) Headache (4.7%) Vomiting (4.7%) Abdominal pain (3.5%) Chest pain (2.4%) Pharyngalgia (2.4%)
Liu et al. [51]  China	32 patients with laboratory confirmed SARS-CoV-2 (25 adults)  Mean age 44 years 48% Male	Single site  Retrospective observational study	Fever (94%) Cough (76%) Myalgia or fatigue (52%) Shortness of breath (40%) Pharyngalgia (24%) Diarrhea or vomiting (8%)

Huang et al. [52] China	32 patients with laboratory confirmed SARS-CoV-2  Median age 49 years 73% Male	Single site  Retrospective and prospective observational study  Data compared between cases requiring ICU care and no ICU care	Fever (98%) Cough (76%) Myalgia or fatigue (44%) Sputum production (28%) Headache (8%) Hemoptysis (5%) Diarrhea (3%)
Xu et al. [53] China	62 patients with laboratory confirmed SARS-CoV-2  Median age 41 years 56% Male	Seven hospitals  Retrospective case series	Cough (81%) Fever (77%) Expectoration (56%) Myalgia or fatigue (52%) Headache (34%) Diarrhea (8%) Hemoptysis (3%) Shortness of breath (3%)
SARS-CoV-2 Surveillance Group Istituto Superiore di Sanità[54] (23 <sup>r</sup> April 2020) Italy	23,188 patients with PCR-confirmed SARS-CoV-2  Median age 81 years 63.3% Male	Patients dying in Italy: 19 regions and 2 autonomous provinces  Retrospective data collection	Fever (75%) Dyspnea (72%) Cough (38%) Diarrhea (6%) Hemoptysis (1%)
Spiteri et al. [55] WHO European Region	38 cases with laboratory-confirmed SARS-CoV-2 (31 with recorded symptoms)  Median age 42 years 65.8% Male	Multiple centers  Retrospective observational study	Fever (64.5%) Cough (45.2%) Weakness (25.8%) Headaches (19.4%) Sore throat (6.5%) Rhinorrhea (6.5%) Shortness of breath (6.5%) Asymptomatic (6.5%)
Zayet et al.[56] France	62 patients  Median age 56 years 39% Male	Single site  Retrospective observational study	Fatigue (94%) Cough (81%) Headache (78%) Fever (76%) Myalgia (61%) Anosmia (52%) Dysgeusia (48%) Rhinorrhea (48%) Diarrhea (39%) Dyspnea (34%)

**Table 2: Characteristics and comorbidities of age-matched hospital and community-based cohorts, according to frailty status.**

Binary variables are presented as count (%) and continuous variables as mean (standard deviation). Frail Hospital = CFS  $\geq$  5; Frail Community= PRISMA7  $\geq$  3.

	Hospital Cohort				Community Cohort			
	Total Sample (n = 210)	Frail (n = 105)	Not Frail (n = 105)	P-value	Total Sample (n=238)	Frail (n=119)	Not Frail (n=119)	P-value
<b>Age</b>	77.9 (6.83)	77.9 (6.64)	77.9 (7.04)	0.91	73.0 (5.86)	73.2 (6.12)	69.8 (4.61)	0.63
<b>Number of females</b>	82 (39%)	41 (39%)	41 (39%)	1.00	82 (34.4%)	41 (34.4%)	41 (34.4%)	1.00
<b>BMI</b>	26.29 (6.28)	26.06 (6.32)	26.5 (6.28)	0.82	26.8 (5.00)	26.8 (5.09)	26.8 (4.92)	0.94
<b>Cardiovascular disease</b>	140 (66.0%)	71 (67.0%)	69 (65.0%)	0.88	37 (15.5%)	28 (23.5%)	9 (7.6%)	0.001
<b>Diabetes</b>	85 (40.4%)	41 (39.0%)	44 (42.0%)	0.67	38 (16.0%)	25 (21.0%)	13 (10.9%)	0.051
<b>Respiratory disease</b>	84 (40.0%)	52 (49.0%)	32 (30.0%)	0.007	50 (21.0%)	35 (29.4%)	15 (12.6%)	0.002
<b>Psychiatric condition</b>	23 (11.0%)	15 (14.0%)	8 (7.0%)	0.18	-	-	-	-
<b>Dementia</b>	40 (19.0%)	35 (33.0%)	5 (4.7%)	1.07x10 <sup>-7</sup>	-	-	-	-
<b>Cancer<sup>a</sup></b>	39 (18.6%)	19 (18.0%)	20 (19.0%)	0.86	27 (14.1%)	25 (23.6%)	2 (2.3%)	1.61x10 <sup>-7</sup>


<sup>a</sup>Cancer data only available for 192 individuals (106 frail and 86 not frail) in the cohort.

**Table 3: COVID-19 symptoms of age-matched hospital and community-based cohorts, according to frailty status**

Binary variables are presented as count (%) and continuous variables as mean (standard deviation). Frail hospital = CFS  $\geq$  5; Frail community-based= PRISMA7  $\geq$ 3; Fever in hospital data ( $\geq$ 37.5°C)  
*P*-values are FDR adjusted at 5%. \*donates significance


	Hospital Cohort					Community Cohort				
	Total Sample (n = 210)	Frail (n = 105)	Not Frail (n = 105)	<i>P</i> -value	OR (95% CI)	Total Sample (n=238)	Frail (n=119)	Not Frail (n=119)	<i>P</i> -value	OR (95% CI)
<b>Delirium</b>	53 (25.2%)	40 (38.1%)	13 (12.4%)	0.013*	3.22 (1.44-7.21)	84 (35.6%)	53 (44.5%)	31 (26.1%)	0.038*	2.29 (1.33-4.00)
<b>Fever</b>	82 (39.0%)	41 (39.0%)	41 (39.0%)	0.90	1.04 (0.55-1.97)	60 (25.4%)	36 (30.3%)	24 (20.2%)	0.174	1.72 (0.95-3.14)
<b>Cough</b>	126 (60.0%)	63 (60.0%)	63 (60.0%)	0.90	1.15 (0.60-2.20)	69 (29.2%)	42 (35.3%)	27 (22.7%)	0.095	1.88 (1.06-3.37)
<b>Fatigue</b>	-	-	-	-	-	164 (69.5%)	92 (77.3%)	72 (60.5%)	0.038*	2.23 (1.27-3.96)
<b>Shortness of Breath</b>	-	-	-	-	-	116 (49.2%)	68 (57.1%)	48 (40.3%)	0.043*	2.00 (1.19-3.39)

**Figure 1: Baseline Characteristics of Study Population according to Frailty in Hospitalised and in Community-based Cohorts (Age Matched Populations)**



For all graphs: F = frail subgroup, NF = non-frail subgroup. (a) Mean age (in years), (b) mean BMI (kg/m<sup>2</sup>) F and NF groups in both sexes combined, female and males, (c) Percentage of females in F and NF groups in hospital cohort. (d) Mean age (in years), (e) mean BMI (kg/m<sup>2</sup>) F and NF groups in both sexes combined, female and males, (f) Percentage of females in F and NF groups in Community-based cohort.

**Figure 2: Proportions of frail and non-frail individuals presenting with symptoms in A) hospital cohort; B) community-based cohort, and C) Odds ratios of effect of frailty on presentation of symptoms.**



## References

1. Guan W, Liang W, Zhao Y *et al*. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. *Eur Respir J* 55: 2000547.
2. Du RH, Liang LR, Yang CQ *et al*. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. *Eur Respir J* 55: 2000524.
3. Wang L, He W, Yu X *et al*. Coronavirus Disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. *J Infect* 2020;
4. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. *JAMA - Journal of the American Medical Association* 2020.
5. CDC. Severe Outcomes Among Patients with Coronavirus Disease 2019 ( COVID-19 ). *MMWR. Morbidity and Mortality Weekly Report* 69 16–19  
<https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6912e2-H.pdf>.
6. The OpenSAFELY Collaborative; Williamson E, Walker A J, Bhaskaran K, *et al*. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *medRxiv* 2020; 20092999.
7. Pawelec G. Age and immunity: What is ‘immunosenescence’? *Exp Gerontol* 2018; 105: 4–9.
8. Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: The potential role of an aged immune system. *Ageing Res Rev* 2017; 36: 1–10.
9. Hofman MR, Van Den Hanenberg F, Sierevelt IN, Tulner CR. Elderly patients with an atypical presentation of illness in the emergency department. *Neth J Med* 2017; 75: 241–246.
10. Malone ML, Hogan TM, Perry A *et al*. COVID-19 in Older Adults: Key Points for Emergency Department Providers. *J Geriatr Emerg Med* 2020; 1: 1–11.
11. Wang D, Hu B, Hu C *et al*. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc* 2020;
12. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. *J Infect* 2020; 80: e14-e18.
13. Fang Y, Han Y, Feng Z *et al*. A comparative-descriptive analysis of clinical characteristics in 2019-Coronavirus-infected children and adults. 2020; 0–2.
14. Tay HS, Harwood R. Atypical presentation of COVID-19 in a frail older person. *Age Ageing* 2020; 1.
15. Osterdahl MF, Lee KA, Lochlainn MN *et al*. Detecting SARS-CoV-2 at point of care: Preliminary data comparing Loop-mediated isothermal amplification (LAMP) to PCR. *medRxiv* 2020; 2020.04.01.20047357.
16. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet* 213AD; 381: 752–62.
17. Fried LP, Tangen CM, Walston J *et al*. Frailty in Older Adults: Evidence for a Phenotype. *Journals Gerontol Ser A Biol Sci Med Sci* 2001; 3: M146-56.
18. NICE. COVID-19 rapid guideline: critical care in adults. *Natl Inst Heal Care Excell* 2020; 2020.
19. O’Hanlon S, Inouye SK. Delirium : a missing piece in the COVID-19. 2020; 1–2.
20. Dunn AM, Hofmann OS, Waters B, Witchel E. Geriatric Medicine Research Collaborative (GeMRC). 2011 395–410 <https://www.gemresearchuk.com/>.
21. Rockwood K, Song X, MacKnight C *et al*. A global clinical measure of fitness and frailty in elderly people. *CMAJ* 2005; Aug 30;173: 489–95.
22. Canadian Study on Health & Aging. *Revis* 2008 2008; 4–6.
23. Raïche M, Hébert R, Dubois MF. PRISMA-7: A case-finding tool to identify older adults with moderate to severe disabilities. *Arch Gerontol Geriatr* 2008; Jul-Aug 47: 9-18.
24. Kopp P. Fit for practice. *Nurs Times* 2001; 97: 41–44.
25. O’Caoimh R, Costello M, Small C *et al*. Comparison of frailty screening instruments in the emergency department. *Int J Environ Res Public Health* 2019; Sep 27;16: 3626.
26. Guan W, Ni Z, Hu Y *et al*. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020; Apr 30;382: 1708-1720.
27. Welch C, McCluskey L, Wilson D *et al*. Delirium is prevalent in older hospital inpatients and associated with adverse outcomes: Results of a prospective multi-centre study on World Delirium Awareness Day. *BMC Med* 2019; Dec 14;17: 229.
28. McMichael TM, Currie DW, Clark S *et al*. Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington. *N Engl J Med* 2020; Mar 27;NEJ.
29. Kapur N. The NHS Long Term Plan. 2020.
30. Bellelli G, Rebori P, Valsecchi MG, Bonfanti P, Citerio G. Frailty index predicts poor outcome in COVID - 19 patients. *Intensive Care Med* 2020; 3–5.

31. Marcantonio ER. Delirium in hospitalized older adults. *N Engl J Med* 2017; Oct 12;377: 1456-1466.
32. Slooter AJC, Van De Leur RR, Zaal IJ. Delirium in critically ill patients. *Handb Clin Neurol* 2017; 141: 449-466.
33. Helms J, Kremer S, Merdji H *et al.* Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med* 2020; Apr 15;NEJ.
34. Mao L, Jin H, Wang M *et al.* Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* 2020; Apr 10;e20.
35. Fu L, Wang B, Yuan T *et al.* Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. *J Infect* 2020; Jun;80: 656-665.
36. Kim H, Chung S, Joo YH, Lee JS. The major risk factors for delirium in a clinical setting. *Neuropsychiatr Dis Treat* 2016; 12: 1787-1793.
37. LaHue SC, James TC, Newman JC, Esmaili AM, Ormseth CH, Ely EW. Collaborative Delirium Prevention in the Age of COVID-19. *J Am Geriatr Soc* 2020; May;68: 947-949.
38. Lawlor PG, Bush SH. Delirium diagnosis, screening and management. *Current Opinion in Supportive and Palliative Care* 8 2014 286-295.
39. Li K, Wohlford-Lenane C, Perlman S *et al.* Middle east respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. *J Infect Dis* 2015; Mar 1;213: 712-22.
40. Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of Host Defense following Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) Pulmonary Infection of Mice. *J Immunol* 2004; Sep 15;173: 4030-9.
41. Wu Y, Xu X, Chen Z *et al.* Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun* 2020;
42. Dubé M, Le Coupance A, Wong AHM, Rini JM, Desforges M, Talbot PJ. Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43. *J Virol* 2018; Aug 16;92: e00404-18.
43. Alenina N, Bader M. ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models. *Neurochem Res* 2019; Jun;44: 1323-1329.
44. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. *ACS Chem Neurosci* 2020; Apr 1;11: 995-998.
45. Office for National Statistics. Overview of the Population. 2019.
46. Clegg A, Bates C, Young J *et al.* Development and validation of an electronic frailty index using routine primary care electronic health record data. *Age Ageing* 2016; May;45: 353-60.
47. House S, Directors R. Testing of NHS staff and household members NHS England and NHS Improvement. 2020; 1-2.
48. COVID-19: investigation and initial clinical management of possible cases - GOV.UK. .
49. Wang D, Hu B, Hu C *et al.* Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc* 2020; 323: 1061-1069.
50. Du Y, Tu L, Zhu P *et al.* Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. *Am J Respir Crit Care Med* 2020; 1-34.
51. Liu K, Fang YY, Deng Y *et al.* Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. *Chin Med J* 2020; May 5;133: 1025-1031.
52. Huang C, Wang Y, Li X *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; Feb 15;395: 497-506.
53. Xu X-W, Wu X-X, Jiang X-G *et al.* Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. .
54. SARS-CoV-2 Surveillance Group I superiore di S. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20 th , 2020. 2020; 4-8.
55. Spiteri G, Fielding J, Diercke M, *et al.* First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. *Eurosurveillance* 2020; 25: 2000178.
56. Zayet S, N'dri Juliette K-O, Royer P-Y, Toko L, Gendrin V, Klopfenstein T. Coronavirus disease 2019: new things to know! *J Med Virol* 2020; 0-3.